What is Amylyx Pharmaceuticals Scaled Net Operating Assets?
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Amylyx Pharmaceuticals's operating assets for the quarter that ended in Mar. 2024 was $44.2 Mil. Amylyx Pharmaceuticals's operating liabilities for the quarter that ended in Mar. 2024 was $89.3 Mil. Amylyx Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $517.5 Mil. Therefore, Amylyx Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was -0.09.
Amylyx Pharmaceuticals Scaled Net Operating Assets Historical Data
The historical data trend for Amylyx Pharmaceuticals's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amylyx Pharmaceuticals Scaled Net Operating Assets Chart
|
Amylyx Pharmaceuticals Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Scaled Net Operating Assets |
|
-4.19 |
-24.28 |
-17.53 |
- |
0.17 |
|
Amylyx Pharmaceuticals Quarterly Data
|
|
Dec19 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Scaled Net Operating Assets |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
0.03 |
0.08 |
0.15 |
0.14 |
-0.09 |
Competitive Comparison of Amylyx Pharmaceuticals's Scaled Net Operating Assets
For the Biotechnology subindustry, Amylyx Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amylyx Pharmaceuticals's Scaled Net Operating Assets Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Amylyx Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Amylyx Pharmaceuticals's Scaled Net Operating Assets falls into.
Amylyx Pharmaceuticals Scaled Net Operating Assets Calculation
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Amylyx Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as
| Scaled Net Operating Assets (SNOA) | | (A: Dec. 2023 ) |
| = | (Operating Assets (A: Dec. 2023 ) | - | Operating Liabilities (A: Dec. 2023 )) | / | Total Assets (A: Dec. 2022 ) |
| = | (146.092 | - | 79.785) | / | 391.453 |
| = | 0.17 |
where
Amylyx Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as
| Scaled Net Operating Assets (SNOA) | | (Q: Mar. 2024 ) |
| = | (Operating Assets (Q: Mar. 2024 ) | - | Operating Liabilities (Q: Mar. 2024 )) | / | Total Assets (Q: Dec. 2023 ) |
| = | (44.164 | - | 89.327) | / | 517.454 |
| = | -0.09 |
where
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amylyx Pharmaceuticals (Amylyx Pharmaceuticals) Business Description
Traded in Other Exchanges
N/A
Address
43 Thorndike Street, Cambridge, MA, USA, 02141
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
Executives
| Joshua B Cohen |
director, officer: Co-Chief Executive Officer |
C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141 |
| Justin B. Klee |
director, officer: Co-Chief Executive Officer |
C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141 |
| Patrick D Yeramian |
officer: Chief Medical Officer |
1815 PARKSIDE CIRCLE SOUTH, BOCA RATON FL 33486 |
| James M Frates |
officer: Chief Financial Officer |
88 SIDNEY ST, CAMBRIDGE MA 021394136 |
| Karen Firestone |
director |
C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE ST., CAMBRIDGE MA 02141 |
| Gina Mazzariello |
officer: Chief Legal Officer |
C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141 |
| Morningside Venture Investments Ltd |
10 percent owner |
MCCARTHY LEGAL SERVICES, 1188 CENTRE STREET, NEWTON CENTRE MA 02459 |
| Milne George M Jr |
director |
|
| Margaret Olinger |
officer: Chief Commercial Officer |
C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141 |
| Viking Global Investors Lp |
10 percent owner |
600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
| Dragsa 96 Llc |
10 percent owner |
55 RAILROAD AVE., GREENWICH CT 06830 |
| Als Invest 1 B.v. |
10 percent owner |
EERSTE WELERINGDWARSSTRAAL 54E, 1017 TP, AMSTERDAM P7 1017 |
| Isaac Cheng |
director |
C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110 |
| Mvil, Llc |
10 percent owner |
22ND FLOOR HANG LUNG CENTRE, 2-20 PATERSON STREET, CAUSEWAY BAY K3 00000 |
| Ole Andreas Halvorsen |
10 percent owner |
600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Amylyx Pharmaceuticals (Amylyx Pharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AMLX has been successfully added to your